{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:53:05Z","timestamp":1780051985166,"version":"3.53.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100021201","name":"European Academy of Dermatology and Venereology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021201","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is a growing trend towards interdisciplinary care (IC) for the management of immune-mediated inflammatory skin diseases (skIMIDs). However, an overview of instruments used to evaluate whether IC is superior to usual care is currently lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This scoping review aims to gain insight into clinician- and patient-reported outcome measures (ClinROMs and PROMs) used in IC for skIMIDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A comprehensive literature search was conducted by screening PubMed, Web of Science and Embase databases from their inception until October 2024. To be eligible, studies needed to have investigated IC for skIMIDs involving dermatologists, and have reported either ClinROMs or PROMs. Two independent reviewers screened all records by title, abstract and full text, with conflicts resolved by a third reviewer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fourteen studies were included in this review. Nine investigated IC for psoriasis (PsO), four for atopic dermatitis (AD) and one for hidradenitis suppurativa. Six PsO studies examined combined dermatology\u2013rheumatology clinics, while four studies explored collaborations with psychiatrists or psychologists for PsO or AD. The remaining IC models were diverse. A total of 49 different ClinROMs and PROMs were reported across the included studies, with 38 being reported by only one study. Except for the Dermatology Life Quality Index (used by 12 studies), body surface area (used by four studies), Psoriasis Area and Severity Index (used by all PsO studies), and Eczema Area and Severity Index or SCORing Atopic Dermatitis (used by all AD studies), the reported ClinROMs and particularly PROMs vary widely.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although several studies describe IC models for skIMIDs, few investigated their impact on ClinROMs or PROMs. The heterogeneous outcomes used pose a challenge for comparison across studies. This review highlights the need for consensus on a core set of outcome measures for IC in skIMIDs to create a common language among the healthcare providers involved, and enhance comparability between studies. Implementing standardized outcome measures for IC in skIMIDs could contribute to the development of evidence-based guidelines and ultimately, improve patient care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Graphical Abstract<\/jats:title>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf153","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T07:45:40Z","timestamp":1744962340000},"page":"415-423","source":"Crossref","is-referenced-by-count":1,"title":["Outcome measures for interdisciplinary care in immune-mediated inflammatory skin diseases: a scoping review"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-5194","authenticated-orcid":false,"given":"Laure","family":"Lemarcq","sequence":"first","affiliation":[{"name":"EVIDENT Research Group, Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7992-0579","authenticated-orcid":false,"given":"Valerie","family":"Reynaert","sequence":"additional","affiliation":[{"name":"EVIDENT Research Group, Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Van den Steen","sequence":"additional","affiliation":[{"name":"EVIDENT Research Group, Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels ,","place":["Belgium"]},{"name":"Biostatistics and Medical Informatics Research Group, Department of Public Health, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Evers-Lebrun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Marinovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University of Zagreb School of Medicine, University Hospital Centre Zagreb , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5656-6236","authenticated-orcid":false,"given":"Diederik","family":"De Cock","sequence":"additional","affiliation":[{"name":"Biostatistics and Medical Informatics Research Group, Department of Public Health, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9252-6004","authenticated-orcid":false,"given":"Jan","family":"Gutermuth","sequence":"additional","affiliation":[{"name":"EVIDENT Research Group, Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"2025081809361209400_ljaf153-B1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-\u00admediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"2025081809361209400_ljaf153-B2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2025081809361209400_ljaf153-B3","doi-asserted-by":"crossref","first-page":"103410","DOI":"10.1016\/j.autrev.2023.103410","article-title":"Immune-mediated inflammatory diseases: common and different pathogenic and clinical features","volume":"22","author":"Monteleone","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2025081809361209400_ljaf153-B4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.091462","article-title":"Pathophysiology and pathogenesis of immune-mediated inflammatory diseases: commonalities and differences","volume":"85","author":"Rahman","year":"2010","journal-title":"J Rheumatol Suppl"},{"key":"2025081809361209400_ljaf153-B5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jval.2015.08.006","article-title":"Clinical outcome assessments: conceptual foundation \u2013 report of the ISPOR Clinical Outcomes Assessment \u2013 Emerging Good Practices for Outcomes Research Task Force","volume":"18","author":"Walton","year":"2015","journal-title":"Value Health"},{"key":"2025081809361209400_ljaf153-B6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","article-title":"Use of existing patient-\u00adreported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report","volume":"12","author":"Rothman","year":"2009","journal-title":"Value Health"},{"key":"2025081809361209400_ljaf153-B7","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s13555-022-00837-4","article-title":"Multidisciplinary Rheuma\u2013Derma Clinics: 5\u2005years of experience at the San Marco Hospital in Catania","volume":"12","author":"Foti","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025081809361209400_ljaf153-B8","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s10067-018-4238-4","article-title":"Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic","volume":"37","author":"Luchetti","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025081809361209400_ljaf153-B9","first-page":"333","article-title":"A multidisciplinary approach in psoriatic disease: the different models of Dermatology-Rheumatology collaborations in Portugal","volume":"46","author":"Mendes-Bastos","year":"2021","journal-title":"Acta Reumatol Port"},{"key":"2025081809361209400_ljaf153-B10","doi-asserted-by":"crossref","first-page":"e13283","DOI":"10.1111\/dth.13283","article-title":"How does the joint dermatology\u2013rheumatology clinic benefit both patients and dermatologists?","volume":"33","author":"Theodorakopoulou","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025081809361209400_ljaf153-B11","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1007\/s12325-023-02667-y","article-title":"The effect of an interdisciplinary dermatological-rheumatological consultation on the outcome of patients with psoriasis with musculoskeletal pain: a prospective, single-center cohort study","volume":"40","author":"von Ahnen","year":"2023","journal-title":"Adv Ther"},{"key":"2025081809361209400_ljaf153-B12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41927-021-00217-z","article-title":"Specialized dermatological-rheumatological patient management improves diagnostic outcome and patient journey in psoriasis and psoriatic arthritis: a four-year analysis","volume":"5","author":"Ziob","year":"2021","journal-title":"BMC Rheumatol"},{"key":"2025081809361209400_ljaf153-B13","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3390\/jcm13082441","article-title":"The impact of shared assistance between dermatology and internal medicine on patients with psoriasis","volume":"13","author":"Garc\u00eda-Malinis","year":"2024","journal-title":"J Clin Med"},{"key":"2025081809361209400_ljaf153-B14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1046\/j.1365-2133.2002.04622.x","article-title":"A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy","volume":"146","author":"Fortune","year":"2002","journal-title":"Br J Dermatol"},{"key":"2025081809361209400_ljaf153-B15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2340\/00015555-1697","article-title":"Effectiveness of interdisciplinary vs. dermatological care of moderate-to-severe psoriasis: a pragmatic randomized controlled trial","volume":"94","author":"Schmitt","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"2025081809361209400_ljaf153-B16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/bjd\/ljae111","article-title":"Effectiveness of a nurse-led one-to-one education programme in addition to standard care in children with atopic dermatitis: a multicentre randomized control trial","volume":"191","author":"Barbarot","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025081809361209400_ljaf153-B17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2340\/00015555-0556","article-title":"Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis","volume":"89","author":"Evers","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"2025081809361209400_ljaf153-B18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/09546634.2020.1782321","article-title":"Multidisciplinary management of chronic atopic dermatitis in children and adolescents: a prospective pilot study","volume":"33","author":"Leong","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025081809361209400_ljaf153-B19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/pde.15533","article-title":"Multidisciplinary atopic dermatitis program: a novel approach to managing difficult-to-control atopic dermatitis patients","volume":"41","author":"Tracy","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"2025081809361209400_ljaf153-B20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijwd.2020.02.006","article-title":"Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice","volume":"6","author":"Touhouche","year":"2020","journal-title":"Int J Womens Dermatol"},{"key":"2025081809361209400_ljaf153-B21","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/acr.25134","article-title":"Improving outcomes of pediatric lupus care delivery with provider goal-setting activities and multidisciplinary care models","volume":"75","author":"Chang","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025081809361209400_ljaf153-B22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11096-019-00870-y","article-title":"Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China","volume":"41","author":"Zhang","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"2025081809361209400_ljaf153-B23","doi-asserted-by":"crossref","first-page":"e1947","DOI":"10.1002\/msc.1947","article-title":"The effect of telerehabilitation-based self-management programme on individuals with scleroderma","volume":"22","author":"Karaku\u015f","year":"2024","journal-title":"Musculoskeletal Care"},{"key":"2025081809361209400_ljaf153-B24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/acr.20448","article-title":"Randomized comparison of a multidisciplinary team care program with usual care in patients with systemic sclerosis","volume":"63","author":"Schouffoer","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025081809361209400_ljaf153-B25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jdv.20321","article-title":"The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality-of-life instruments: a systematic review","volume":"39","author":"Vyas","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025081809361209400_ljaf153-B26","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris \u2013 Part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025081809361209400_ljaf153-B27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025081809361209400_ljaf153-B28","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","article-title":"The HOME Core outcome set for clinical trials of atopic dermatitis","volume":"149","author":"Williams","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025081809361209400_ljaf153-B29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/jamadermatol.2024.1162","article-title":"Measuring signs of atopic dermatitis in clinical practice: A HOME-CP consensus statement","volume":"160","author":"Jacobson","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2025081809361209400_ljaf153-B30","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I \u2013 systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025081809361209400_ljaf153-B31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00403-011-1172-6","article-title":"Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic","volume":"304","author":"Velez","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"2025081809361209400_ljaf153-B32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ced.14390","article-title":"Analysis of the first 5\u2005years of an interdisciplinary Rheumatology-Dermatology clinic","volume":"46","author":"Argobi","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2025081809361209400_ljaf153-B33","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/ced.13766","article-title":"Impact of a combined dermatology\u2013rheumatology clinic on management of autoimmune connective tissue disorders","volume":"44","author":"Campagna","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"2025081809361209400_ljaf153-B34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMp1511701","article-title":"Standardizing patient outcomes measurement","volume":"374","author":"Porter","year":"2016","journal-title":"N Engl J Med"},{"key":"2025081809361209400_ljaf153-B35"},{"key":"2025081809361209400_ljaf153-B36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-019-00496-w","article-title":"Investigator and patient global assessment measures for psoriasis clinical trials: a systematic review on measurement properties from the International Dermatology Outcome Measures (IDEOM) initiative","volume":"21","author":"Perez-Chada","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2025081809361209400_ljaf153-B37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025081809361209400_ljaf153-B38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3899\/jrheum.170150","article-title":"Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group","volume":"44","author":"Ogdie","year":"2017","journal-title":"J Rheumatol"},{"key":"2025081809361209400_ljaf153-B39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/jdv.18696","article-title":"Initiating value-based healthcare in psoriasis: proposing a value-based outcome set for daily clinical practice","volume":"37","author":"Hilhorst","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025081809361209400_ljaf153-B40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1745-6215-15-247","article-title":"Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a \u2018core outcome set\u2019","volume":"15","author":"Prinsen","year":"2014","journal-title":"Trials"},{"key":"2025081809361209400_ljaf153-B41","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3899\/jrheum.170148","article-title":"Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) survey: benefits and challenges of combined rheumatology-dermatology clinics","volume":"44","author":"Okhovat","year":"2017","journal-title":"J Rheumatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf153\/62954824\/ljaf153.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/3\/415\/62954824\/ljaf153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/3\/415\/62954824\/ljaf153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T13:36:27Z","timestamp":1755524187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/3\/415\/8116193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4,18]]},"published-print":{"date-parts":[[2025,8,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf153","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,18]]}}}